Factor 9 activity-13368

Test info

  
Factor 9 activity
  
13368
  
LAB13368
  
F9
  
Antihemophilic
Antihemophilic factor B
Factor IX activity
  

To evaluate an isolated prolonged APTT and to document specific factor IX deficiency.

Specimen

  
  • Ideally the patient should not be on anticoagulant therapy.
  • Avoid warfarin (Coumadin®) therapy for two weeks prior to the test and heparin, direct Xa, and thrombin inhibitor therapies for about three days prior to testing.
  
Sodium citrate (Na cit) plasma
  
  
1.0 mL
  
  • Do not draw from an arm with a heparin lock or heparinized catheter.
  • Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.
  • Evacuated collection tubes must be filled to completion to ensure a proper blood-to-anticoagulant ratio.
  • The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood.
  • A discard tube is not required prior to collection of coagulation samples unless the sample is collected using a winged (butterfly) collection system.
    • With a winged blood collection set a discard tube should be drawn first to account for the dead space of the tubing and prevent under-filling of the evacuated tube.
  • When noncitrate tubes are collected for other tests, collect sterile and nonadditive (red-top) tubes prior to citrate (blue-top) tubes. Any tube containing an alternative anticoagulant should be collected after the blue-top tube. Gel-barrier tubes and serum tubes with clot initiators should also be collected after the citrate tubes.
  • If the patient's hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted.
  
  1. Spin within two (2) hours of sample collection
  2. Transfer plasma to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as Na cit plasma
  3. Freeze
  

Frozen

  
  • Severe hemolysis
  • Improper labeling
  • Clotted specimen
  • Specimen diluted with I.V. fluids
  • Samples thawed in transit
  • Improper sample type
  • Sample out of stability

 

Performance

  
LabCorp Burlington (086298): R-LC
  
Daily
  
2 - 3 days
  

Factor IX activity is determine utilizing an aPTT-based one-stage clotting time assay. Factor IX-depleted plasma is used as the substrate, and the clotting time with the patient plasma is compared to the clotting time of normal pooled plasma.

Clinical and Interpretive info

  

60 - 177%

Billing

  
85250
  
Result 3187-2

Tracking

  
03/29/2019
  
03/30/2021
  
12/29/2023